API | elobixibat

elobixibat Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Elobixibat is an inhibitor of the ileal bile acid transporter (IBAT), undergoing development in clinical trials for the treatment of chronic constipation and irritable bowel syndrome with constipation (IBS-C). ^Wikipedia

Chemistry

SMILES: CCCCC1(CCCC)CN(c2ccccc2)c2cc(SC)c(OCC(=O)N[C@@H](C(=O)NCC(=O)O)c3ccccc3)cc2S(=O)(=O)C1
InChIKey: XFLQIRAKKLNXRQ-UUWRZZSWSA-N
Mol. Mass: 695.9
ALogP: 6.14 Partition coefficient
ChEMBL Molecule:
elobixibat

More Chemistry

Pharmacology

Mechanism of Action:
- Ileal sodium/bile acid cotransporter (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

a3309 | a-3309 | azd-7806 | elobixibat

Organizations (8)

Research & Development (8)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (1)

Constipation

Experimental Indications - Clinical Trial Phases 1-4 (3)

Constipation (Phase 4)

Dyslipidemias (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 13
# of Trial Organizations: 8

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue